Notizie AIOM – anno XVI n. 667
NCCN Recommends Regorafenib Dose Escalation in Metastatic CRC
March 16, 2018 - The NCCN has updated its colorectal cancer (CRC) guidelines, recommending a weekly regorafenib dose-escalation strategy beginning at 80 mg and ending at 160 mg for previously treated patients with metastatic CRC (mCRC). The new dosing scheme calls for a ...Leggi tutto
FDA Grants Erdafitinib Breakthrough Designation for Urothelial Carcinoma
March 15, 2018 - The FDA has granted a breakthrough therapy designation to erdafitinib for the treatment of metastatic urothelial carcinoma, according to Janssen, the manufacturer of the oral pan-FGFR tyrosine kinase inhibitor. The designation, which will expedite the review ...Leggi tutto
EMA Management Board: highlights of March 2018 meeting
March 16, 2018 - At its 15 March meeting in London, the European Medicines Agency’s (EMA) Management Board endorsed the 2017 report on the implementation of the policy on veterinary medicines for minor use minor species (MUMS) / limited markets. The policy aims to ...Leggi tutto
Obese Castration-Resistant Prostate Cancer Patients may be at a lower risk of all-cause mortality: Results from the SEARCH Database
At the population level, obesity is associated with prostate cancer (PC) mortality; however, some studies found higher body mass index (BMI) is associated with better long-term PC outcomes among men with metastatic castration-resistant PC (mCRPC). We tested whether obesity ...Leggi tutto